Thursday November 29

West Coast Day 2

Emerging & Reemerging Vaccine Targets

Therapeutic Immunotherapy Approaches

Vaccine Technology & Manufacture

Immuno-Oncology
08:40

Understanding mechanisms of resistance to checkpoint inhibitors – how can this inform combinatorial approaches?

Vaccine Development
09:10

A novel approach to developing single dose and safe vaccines for emerging infectious diseases

  • In vivo production of VLPs allows them to be more readily recognized by the immune system
  • Safety and durability of vaccines demonstrated in HIV clinical trials
  • Platform can be applied to multiple vaccine targets including; Ebola, Zika and Lassa
  • Differs from other platforms as there is no need for adjuvants and is thermally and genetically stable
Delivery, Bioprocessing & Manufacturing
09:10

Expanding Vaccine Effectiveness with Needle-Free Delivery

  • Commercially available Needle-free delivery systems
  • Established clinical efficacy with commercial vaccines
  • Helping Nucleic Acid based vaccines toward licensure
Delivery, Bioprocessing & Manufacturing
09:40

A DNA vaccine platform to rapidly produce countermeasures against emerging viral threats

  • Describe a highly scalable manufacturing process for the rapid production of DNA-based vaccines for emerging infectious diseases
  • Discuss the stability profile of our DNA-based product
  • Offer a real-life example of a rapid response to an infectious disease – Zika
10:10

Morning Networking Break & Poster Session

Interactive Roundtables

Choose one of our roundtables for interactive discussions with like-minded peers tackling the similar challenges in:
11:30

Challenges for next generation adjuvants

11:30

Clinical data integration – How do we deal with the volume of data generated by recent I-O trials?

11:30

Considerations for successful cancer immunotherapy in aged hosts

11:30

Development of predictive biomarkers to determine optimal combinations in precision immunotherapy

11:30

Discovery of pre-clinical genomic biomarkers of safety and efficacy in vaccine research, design and development

11:30

How can we improve speed, delivery and cost of next generation cancer vaccines?

11:30

How can we streamline the vaccine manufacturing process to respond quickly to pandemics?

11:30

Improving the accuracy of neoantigen identification

11:30

Legal considerations for partnering with government bodies, pharma and biotechs

11:30

What are the next steps when immunotherapy trials fail after receiving accelerated approval?

11:30

What are we doing to target potential responders or enrich for potential responders in immuno-oncology?

12:30

Networking Lunch & Poster Session

Antibodies for Infectious / Autoimmune Diseases

Antibodies in Cancer

Manufacturing Immunotherapies

Vaccine Development
2:40

Development of trispecific antibodies for the treatment of HIV and potential for application to other infectious diseases

  • Background on broadly neutralizing antibodies to HIV addressing potency and breadth of coverage
  • Potential for combinations of antibodies to provide optimum coverage for therapy or prevention of HIV infection
  • Pre-clinical development and testing of a trispecific anti-HIV antibody molecule
  • Update on clinical development and testing of a trispecific anti-HIV antibody molecule
Immuno-Oncology
3:10

Bispecific Technology for Multiple Avenues of T-cell Activation

  • Checkpoint bispecifics to improve therapeutic index: PD1 x CTLA4
  • Triple checkpoint blockade: LAG3 x CTLA4 bispecific plus anti-PD1
  • Checkpoint plus costim.: PD1 x ICOS
  • Potency-tuned IL15 for prolonged T cell stimulation
3:40

Afternoon Networking Break

Antibody Technology & Delivery

Vaccine Development
4:10

Harnessing Natural Immunity to Create Breakthrough Therapies for Infectious Diseases

  • These antibodies are isolated from individuals with natural immunity against pathogens.
  • Antibody sequences are derived from unmodified heavy and light chain human B lymphocyte sequences that have undergone ontogeny and selection inside a human body.
  • Antibodies derived as a result of a human immune response are expected to exhibit high affinity, ideal safety and pharmacokinetics.
  • XBiotech’s discovery and production technologies help bring these novel therapeutics from bench to bedside in a relatively short timeframe
Delivery, Bioprocessing & Manufacturing
4:10

Advances in technology and ongoing challenges in the development of next generation antibody therapeutics

  • Overview of status of bispecific research – advantages of bispecific therapies vs two monotherapies
  • Alternative scaffolds for bispecific antibodies
  • Manufacturing strategies and challenges – production, engineering and stability
Vaccine Development
4:40

Development of a broadly neutralizing monoclonal antibody with extended half-life technology for the prevention of RSV in all infants

  • Overview of early discovery work
  • Updates from 2 completed clinical trials
  • New work on International Network for Optimal Resistance Monitoring (INFORM) RSV in collaboration with ReSViNET
Immuno-Oncology
4:40

Biologic and clinical activity of first in class ICOS agonist antibody in combination with checkpoint inhibitors

  • Preclinical rationale for development of JTX-2011, an ICOS agonist
  • Rationale for combinations with PD-1 inhibitors, CTLA-4 inhibitors, and vaccines
  • Clinical and biomarker data for JTX-2011 in patients with advanced solid tumors that supports further development
Delivery, Bioprocessing & Manufacturing
4:40

Development of active immunoprophylaxis with DNA-encoded monoclonal antibodies (dMAb)

Dr Laurent Humeau, Senior Vice President, Research and Development, Inovio Pharmaceuticals
Vaccine Development
5:10

Immune Dampening and Refocusing for deriving novel biologics for difficult and unmet infectious disease and oncology applications

  • Addressing the problem of evolved immunodominance in antigenic structures
  • What is deceptive Imprinting and how does it work?
    • e.g. what is its evolutionary benefit?
  • What are the immuno-chemical-physical characteristics that drive it?
    • e.g. how can these be identified today and tomorrow?
  • What processes and technologies are available to overcome this evolved pathogen survival strategy?
    • Review Immune refocusing technology
Delivery, Bioprocessing & Manufacturing
5:10

Engineering bi-specific antibodies

5:40

Chair’s closing remarks of day two followed by networking drinks reception and Meet & Greet with key speakers

last published: 18/Oct/18 12:55 GMT

 

 

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com